[Special Stock] Osteonic Posts Highest Quarterly Sales in Q4 Last Year, Anticipation Grows for Full-Scale US Market Sales

Osteonic is showing strong performance. This is interpreted as being influenced by securities firms' analysis that the company recorded its highest sales in the fourth quarter of last year and that sales to the U.S. market will begin in earnest this year.

As of 2:35 PM on the 18th, Osteonic was trading at 8,080 KRW, up 540 KRW (7.16%) compared to the previous trading day.

Osteonic continues its steady growth, having recorded its highest quarterly sales in history in the fourth quarter of last year. Jaeyoon Han, a researcher at KB Securities, stated, "Osteonic's fourth-quarter results last year showed sales of 9.7 billion KRW and operating profit of 1.9 billion KRW. Especially, the fourth quarter being the peak season and the smooth ramp-up of its own brand were major factors contributing to the strong performance."

Positive trends are also continuing in overseas markets. Researcher Han evaluated, "Given that sales to key overseas clients such as Zimmer and B. Braun have not yet fully started, these results are even more meaningful."

However, operating profit decreased compared to the same period last year and the previous quarter. Regarding this, he explained, "The decline in profitability is due to proactive hiring to increase production volume, which is a temporary issue and unrelated to any fundamental deterioration."

Sales to Zimmer in the U.S., which was considered a key investment point for Osteonic, are expected to begin in earnest from the first quarter of this year. Researcher Han said, "Starting with the first shipment in March this year, we expect to record significant annual sales."

In particular, although new medical devices require a certain ramp-up period after launch, it is anticipated that this period will be shortened by leveraging Zimmer’s strong distribution network.

Entry into the U.S. market is also positive from a profitability perspective. Researcher Han explained, "The U.S. market commands overwhelmingly higher prices compared to other countries, so once sales to the U.S. market begin in earnest, additional profitability improvements are expected."